BridgeMD
New treatment option for Stage I Testicular Seminoma
Official title Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
ClinicalTrials.gov ID: NCT05500391
What this study is testing
- What it's testing
- This is a multicenter, interventional, randomized study among adult patients recently diagnosed with a rare tumor (\<12 months). The study will aim to compare compliance with the personalized post-treatment surveillance plan, established for each patient according to national guidelines, when the surveillance is conducted in person by a hospital-based physician (control arm) or remotely by a trained nurse (experimental arm).
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Positive diagnosis (anatomopathology) of tumor within 12 months
- Patient 18 years of age or older
- Patient with one of the following conditions:
- Desmoid fibromatosis of the abdominal wall operated on or under active surveillance
- Stage I testicular seminoma (whether or not treated with carboplatin AUC7)
You likely can't join if
- Contraindication to imaging tests required for the surveillance plan
- No telephone
- Patient under guardianship or curatorship
See the full eligibility criteria
- Positive diagnosis (anatomopathology) of tumor within 12 months
- Patient 18 years of age or older
- Patient with one of the following conditions:
- Desmoid fibromatosis of the abdominal wall operated on or under active surveillance
- Stage I testicular seminoma (whether or not treated with carboplatin AUC7)
- Stage I non-seminomatous germ cell tumor (with or without adjuvant BEP chemotherapy)
- Operated GIST with low risk of relapse
- Rare gynecological tumors (sex cord and stromal tumors; germ cell tumors of the ovary, clear cell adenocarcinoma, mucinous adenocarcinoma of the ovary, borderline tumors, small cell carcinoma, ovarian and uterine...
- Low-grade glioma, operated
- Low-grade neuroendocrine tumor, treated by surgery alone
- Patient who has given consent to participate in the study
- Contraindication to imaging tests required for the surveillance plan
- No telephone
- Patient under guardianship or curatorship
The study team makes the final eligibility decision.
Where it's taking place
- Amiens, France
- Caen, France
- Lille, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Amiens, France; Caen, France; Lille, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.